Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 44 % of short-term debt in 2024; threshold 65 %.
-
Busy address KBO
41 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
PREMIUM PHARMA from Elsene, company number BE0896401843, closed financial year 2024 with a result of € 24,667 after tax. For that financial year PREMIUM PHARMA recorded a gross margin of € 99,952 and equity of € 17,605. Compared with financial year 2023, the result moved from € -40,178 to € 24,667. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on October 31, 2025.
€ 17,605
▲ € 24,667 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 24,667
▲ still € 40,178 loss in 2023
Profit after tax over the fiscal year.
€ 333
▼ 94% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € -995.
People and assets in 2024
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 62,355
▲ 48% vs 2023
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 894
▼ 24% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 69,585
▼ 27% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 1,009
▼ 86% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 38,761 | € 23,162 | € 22,576 | € 99,952 | ▲ € 77,375 |
| Profit after taxes | € 8,655 | € 443 | € -40,178 | € 24,667 | ▲ € 64,844 |
| Equity | € 32,673 | € 33,116 | € -7,062 | € 17,605 | ▲ € 24,667 |
| Total debts | € 286,984 | € 260,942 | € 256,784 | € 70,594 | ▼ 73% |
| Cash | € 36,319 | € 44,197 | € 5,969 | € 333 | ▼ 94% |
| Land & buildings | € 79,200 | € 75,600 | € 72,000 | - | |
| Retained profit | € 14,073 | € 14,516 | € -25,662 | € -995 | ▲ € 24,667 |
| Bank debt | € 165,140 | € 168,064 | € 129,037 | € 0 | ▼ 100% |
| Balance sheet total | € 319,657 | € 294,058 | € 249,722 | € 88,198 | ▼ 65% |
Key figures of PREMIUM PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to PREMIUM PHARMA?
What happened at PREMIUM PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 24,667. filed late Source: NBB ↗
- New establishment in Zaventem. KBO
- New establishment in Elsene. KBO
- Start of the company according to the CBE. KBO
In short
From € 8,655 profit in 2021 to € 24,667 profit in 2024.
Paid € 4,064 in corporate taxes since 2021.
Best year ever: 2024, with € 24,667 profit.
A new publication or filing at PREMIUM PHARMA? We notify you, reason included.
Follow PREMIUM PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PREMIUM PHARMA is Olivier Lebbink. Olivier Lebbink is also behind PREMIUM CONSULTING & MANAGEMENT and PREMIUM PHARMA RETAIL.
Directors
According to the 2024 annual accounts
Establishments
Establishment units
Physical locations of this company
Louizalaan 163
1050 Elsene
Excelsiorlaan 61
1930 Zaventem
Active since 1 May 2015
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 41 companies are registered at this address.
All companies at this address →Triple S Plus
GARSIAL TRADE
€ -2,313 gross margin · 2025
FESCACOM IT
€ 33,848 gross margin · 2025
FLAVES
€ 30,643 gross margin · 2024
C for Change
+36 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0896.401.843
- VAT number
- BE 0896.401.843
- Registered office
- Louizalaan 163, 1050 Elsene
- Names & denominations
- PREMIUM PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 12 March 2008
- Peppol
- Active · Active since 23 Aug 2024
- Activities · NACE
Organisatie van congressen en beurzen
Administratieve en ondersteunende activiteiten ten behoeve van kantoren
Arbeidsbemiddeling
Beroepsopleiding
Activiteiten van reclamebureaus
Diverse administratieve activiteiten ten behoeve van kantoren
Fotokopiëren, documentvoorbereiding en andere gespecialiseerde ondersteunende activiteiten ten behoeve van kantoren